Pharma App Benchmarking 2014 - How Pharma companies make use of mobile apps

The report analyzes the global app publishing activities of the 12 leading Pharma companies on Android and iOS devices. It provides a detailed picture of which app categories Pharma companies concentrate on, how many apps they have published, which user groups they target, how they organize their app business and how successful they are.

The report analyzes app publishing activities on three levels:

Level 1 - Pharma app publisher industry view: The first chapter provides an overview of how Pharma companies are making use of the app channel today and how this has changed over the last 12 months.

Level 2 - Comparison of Pharma app activities: In the second part of the report, the companies are being analyzed on a company level and compared against each other.

Level 3 - Pharma app publisher profiles: The third part provides detailed profiles of the companies’ app activities. It also highlights the most successful apps for professional and private users (based on downloads).

Companies in scope: 

• Abbvie/Abbott
• Astra Zeneca
• Bayer HealthCare
• Bristol-Myer Squibb
• GlaxoSmithKline
• Johnson&Johnson
• Merck
• MSD
• Novartis
• Pfizer
• Roche
• Sanofi-Aventis

Apps in scope: 

All apps available in the Apple App Store and in Google Play, which have been published by one of the 12 pharma companies. 

Regional scope: 

• Global 

Target groups:

Anybody who is interested in mobile health, esp. pharma the industry: app developers, product managers, digital and innovation managers, investors or analysts.

Why read the report:

• Analysis of 736 apps (iOS & Android) of the top pharma companies
• Detailed benchmarking of the app activities of top pharma companies
• Benchmarking includes the comparison of downloads, active users, target groups, app category
• Performance of the app portfolio of top 12 pharma companies, app publishing strategy, country focus
• Profiles of all pharma company app portfolios including top apps that target private and professional users
• Based on the results of the benchmarking the report provides options for a better app portfolio performance for pharma apps 

Related products and services:

• Diabetes App Market Report 2014
• Health Insurance App Benchmarking 2015
• 
  

View Full TOC: https://wiseguyreports.com/reports/pharma-app-benchmarking-2014-how-pharma-companies-make-use-of-mobile-apps

Conatct Us:

Norah Trent

Partner Relation & Marketing Manager

+1 – 646-845-9349

norah.trent@wiseguyreports.com

www.wiseguyreports.com

Know Us:

Facebook | LinkedIn | Twitter | Blog | Healthcare Blog

Global CTC Technologies market is predicted to increase at a CAGR of 25.91% for the analysis period 2010-2020

Circulating tumor cells (CTCs) are cells that have shed into the vasculature from a primary tumor and circulate in the bloodstream. CTCs thus constitute seeds for subsequent growth of additional tumors (metastasis) in vital distant organs, triggering a mechanism that is responsible for the vast majority of cancer-related deaths. CTCs were observed for the first time in 1869 in the blood of a man with metastatic cancer by Thomas Ashworth, who postulated that “cells identical with those of the cancer itself being seen in the blood may tend to throw some light upon the mode of origin of multiple tumours existing in the same person”.

This report on Circulating Tumor Cells (CTC) Technologies gives a market insight into technologies and services used for cancer detection. The market is analyzed by Cancer type into Prostate, Breast and Other; and by Function into Prognostics, Diagnostics and Therapy Management. The report serves as a guide to CTC industry, covering more than 190 companies that are engaged in CTC studies/screening, products and services. Major Contract Research Organizations, Research Institutes and Universities serving the CTC market are also covered in the corporate directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. Compilation of Worldwide Patents related to CTC Technologies is also provided. A global perspective is presented along with regional analysis covering the regions of North America, Europe, and Asia-Pacific with 40 exclusive graphically represented exhibits.

Global CTC Technologies market is predicted to increase at a CAGR of 25.91% for the analysis period 2010-2020. Cancer is a growing scourge as about 11 million people are being diagnosed with cancer every year and estimates say that are likely to be about 16 million new cases every year by 2020. Johnson & Johnson, through its Veridex LLC division, is the only company with FDA approval in the CTC Technologies area. The CellSearch's CTC test kit is valuable in assessing the prognosis of patients suffering from metastatic stage in breast cancer, prostate cancer and colorectal cancer. Several companies throughout the world have products in clinical trials and are expected to compete vigorously in the next few years with improvised products.

Report by Chapter

1. Scope and Methodology: This chapter provides information regarding the research methodology, limitations of the study, market measuring units and exchange rates used.
2. Report Synopsis: Synopsis of the report summarizes the global Circulating Tumor Cells (CTC) Technologies market, by Cancer Type and Function Type. Global market is also analyzed by geographic regions including North America, Europe, Asia-Pacific and Rest of World. The chapter provides market values (2010 - 2020) in US$ for each geographic region. A List of major Global companies is also provided.
3. Market Dynamics: Market Dynamics chapter provides information on global markets for Circulating Tumor Cells (CTC) Technologies. The chapter includes global market analysis (in US$) by geographic region; analysis of each region by both Cancer type and Function type; a brief business profile of (59) major global companies; and a report of corporate activities such as mergers and acquisitions, partnerships, new product developments/launches, etc. The section includes key market trends and an industry outlook.
4. Product/Technology Research: This chapter gives an insight into Circulating Tumor Cells (CTC) Technologies market including definitions, segmentation and applications. The chapter also includes product trends and potential opportunities. Various CTC detection methods, and the challenges faced by the industry are also discussed. Various research activities in the field of CTC Technologies finds a mention in this chapter.
5. Corporate Directory: This chapter provides a global region-wise list of 150 plus companies, CROs, hospitals and academic institutions that offer Circulating Tumor Cells (CTC) Technologies products and/or services
6. Patents Information: This chapter provides a compilation of worldwide patents related to Circulating Tumor Cells (CTC) Technologies.

Report Highlights
Global CTC Technologies market is predicted to increase at a CAGR of 25.91% for the analysis period 2010-2020. Cancer is a growing scourge as about 11 million people are being diagnosed with cancer every year and estimates say that are likely to be about 16 million new cases every year by 2020. Johnson & Johnson, through its Veridex LLC division, is the only company with FDA approval in the CTC Technologies area. The CellSearch's CTC test kit is valuable in assessing the prognosis of patients suffering from metastatic stage in breast cancer, prostate cancer and colorectal cancer. Several companies throughout the world have products in clinical trials and are expected to compete vigorously in the next few years with improvised products.

Why Buy This Report?
This report may help Strategists, Investors, Laboratories, Contract Research Organizations, Biotechnology & Healthcare Companies, Academic Professionals, Drug Approval Authorities, and Other Organizations to –

• Identify Market Opportunities
• Review and Analyze Global and Regional Markets
• Gauge Market Potential for your Products
• Identify Competition
• Use Market Research for exploring new areas
• Acquire Meaningful Guidelines for Strategic Planning
• Gear up for Market Entry

Get Actionable Information Analytics and data presented in each report pertain to several parameters such as –

• Global and Regional Market Sizes, Market Shares, Market Trends
• Product (Global and Regional) Market Sizes, Market Shares, Market Trends
• Technology Trends
• Corporate Intelligence

Key Companies By Sales, Brands, Products

• Other Strategic Business Affecting Data​Companies Discussed
• 13+ Circulating Tumor Cells (CTC) Technologies Company Insight Profiles
• 194+ Company Directory Listing 

Company Insight Profiles List

• Abnova Corporation (Taiwan)
• AVIVA BioSciences Corporation (USA)
• BioCep Ltd. (Israel)
• Canopus Bioscience Ltd. (Canada)
• Exelixis, Inc. (USA)
• Fluxion Biosciences, Inc. (USA)
• Ikonisys, Inc. (USA)
• Miltenyi Biotec, Inc. (USA)
• On-Q-ity (USA)
• RareCells SAS (France)
• ScreenCell (France)
• Telo VISION, LLC (USA)
• Veridex, LLC (USA)

Report Link: https://wiseguyreports.com/reports/circulating-tumor-cells-ctc-technologies-market-research-report

High Throughput Screening - Market Research

High Throughput Screening (HTS) is a drug-discovery process widely used in the pharmaceutical industry. It leverages automation to quickly assay the biological or biochemical activity of a large number of drug-like compounds. The process by which thousands of compounds that possess the potential of emerging as a new drug are tested using automated machines.

The main objective of carrying out HTS is to remove the inactive compounds at the initial stage and accumulate the active compounds called hits. These hits are then put through various tests to obtain the leads. The process of HTS when employed on half a million compounds, for example, would provide 300 - 400 hits and this in turn would create 3 to 4 Leads. Ultra High Throughput Screening (uHTS) can be carried out in cell based assays under various physiological environments. This finds application in screening of libraries, holding compounds in millions. Due to various structural effects the primary hits are to be carefully evaluated. When counter screening is employed in cell assays with orthogonal structure, the false positives can be eliminated with ease. Varied read out expertise and cellular setting are utilized during the development of assays. When all these assays gets adapted to the 1536 microtiter plate, the process of counter screening at initial step of hit detection process can be accomplished. Thus early hit detection and lead profiling can be achieved.

High Content Screening (HCS) is the latest drug discovery process that makes use of living cells for drug discovery. It is a highly sophisticated method that attempts to derive maximum information from a single experiment. It uses the information provided by modern cell biology. The use of refined high-resolution microscopes and robots as auto handlers facilitates efficient information retrieval. The analysis of information and the screening process are fully automated, which is an exception as compared to other life sciences technologies.

Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the growing alliances between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc. The computer platforms generated by such companies help in managing and analyzing the huge amounts of data produced through High Throughput Screening (HTS) and other computational techniques. Effective R&D strategy involves efficient data management and implementation plans. The new technologies promise improved efficacy, decreased toxicity in patients, and reduced time frames and expenditures.

Changing business paradigms brought in by globalization and liberalization are making pharmaceutical companies change strategies for sustenance and growth. Many companies are venturing into HTS studies instead of going for alliances, to become self-sufficient and reduce costs. The R&D wings are increasingly becoming target oriented to face the numerous challenges posed in the drug discovery and development industry.

Global High through put screening market is especially driven by the advancements in HTS technologies and the increasing usage of innovative techniques such as Bioinformatics and Lab-on-a-Chip/Microfluidics. The success of Human Genome Project and latest findings in genomics and proteomics are creating an enormous market for HTS by identifying huge number of drug targets. Currently, automation in High through put screening Market industry is in high gear. The companies are investing heavily in laboratory automation products such as HTS software, database systems, robotics arms and robot based workstations.

Global HTS market is projected to grow at a high rate of 11.86% compounded annually from 2005 through 2020.Global HTS market growth is especially driven by the advancements in HTS technologies and the increasing usage of innovative techniques such as Bioinformatics and Lab-on-a-Chip/Microfluidics. The success of Human Genome Project and latest findings in genomics and proteomics are creating an enormous market for HTS by identifying huge number of drug targets. Currently, automation in HTS industry is in high gear. The companies are investing heavily in laboratory automation products such as HTS software, database systems, robotics arms and robot based workstations. Strategic partnerships between pharmaceutical and biotechnology companies are the order of the day, and the trend is increasing globally. Another significant trend is the alliances between Pharma and Biotech companies and information technology companies such as Microsoft, IBM, Oracle, Sun, and Infosys, etc.

The computer platforms generated by such companies help in managing and analyzing the huge amounts of data produced through High Throughput Screening (HTS) and other computational techniques. Effective R&D strategy involves efficient data management and implementation plans. The new technologies promise improved efficacy, decreased toxicity in patients, and reduced time frames and expenditures. Changing business paradigms brought in by globalization and liberalization are making pharmaceutical companies change strategies for sustenance and growth. Many companies are venturing into HTS studies instead of going for alliances, to become self-sufficient and reduce costs. The R&D wings are increasingly becoming target oriented to face the numerous challenges posed in the drug discovery and development industry. High Throughput Screening report is an ideal research tool providing strategic business intelligence to the corporate sector.

Read Full TOC: https://wiseguyreports.com/reports/high-throughput-screening-market-research-report

Parkinson’s Disease - Global Drug Forecast and Market Analysis 2022

 Parkinson’s disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, and postural instability. As the second most common neurodegenerative disorder, Parkinson’s disease may affect individuals of any age but prevalence is increased with age and it is most common in the elderly. 

It is expected that the prevalence of Parkinson’s disease in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and Brazil will increase from 3.2m people in 2012 to 4.3m people in 2022, driven by an aging population in all markets. Dopaminergic therapies have been fairly effective in treating bradykinesia, but several unmet needs remain. Some needs will be met during the forecast period from 2012-2022, while others, such as the need for disease-modifying drugs, will remain. GlobalData expects that advancements will be made in levodopa administration and that four new molecular entities will be introduced to the market by 2022, these factors along with increased patient numbers from an aging population will drive the market during the forecast period.

Parkinson’s Disease - Global Drug Forecast and Market Analysis to 2022 is a market Research Report published by a well known research publisher and Highlights Key Questions as:

- According to KOLs, what are the most important unmet needs in PD? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2022?
- With five new product launches, three of which address the needs of advanced stage patients, which products are forecast to generate the highest sales over 2012-2022?
- What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
- An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?
- What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?

Key Findings

- Population increases, especially in the elderly, will be a key driving force in the global PD market.
- With several small biotech and pharmaceutical companies involved in mid-stage development of PD products, there will be ample opportunity for partnerships with Big Pharma.
- Levodopa based therapy will remain the gold standard of care with advancements in administration, including the introduction of slow-release formulations and an emergency use inhaler.
- Several unmet needs are expected to remain after the forecast period, as advancements in the control of non-motor symptoms and in the development of disease-modifying therapies are lagging.

Scope

- Overview of Parkinson’s disease, including etiology, pathophysiology, motor and non-motor symptoms, and quality of life.
- Annualized Parkinson’s disease market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for ten years to 2022.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD market.
- Pipeline analysis: comprehensive data split across different Phases and emerging trends, specifically Newron’s safinamide, Biotie and UCB’s tozadenant, Civitas’ CVT-301, Impax’s Rytary (IPX066), Bial’s opicapone, Novartis’ mavoglurant (AFQ056), and Intec’s CD/LD-GR.
- Analysis of the current and future market competition in the global Parkinson’s disease market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

 Read Full TOC: https://wiseguyreports.com/reports/pharmapoint-parkinson-s-disease-global-drug-forecast-and-market-analysis-to-2022

Swine Influenza Global Clinical Trials Review, H2, 2014

“Swine Influenza Global Clinical Trials Review, H2, 2014" provides data on the Swine Influenza clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Swine Influenza. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.

The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Swine Influenza. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the team of industry experts.

Scope- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy- Understand the dynamics of a particular indication in a condensed manner- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more- Obtain discontinued trial listing for trials across the globe- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies.

Report Link: https://wiseguyreports.com/reports/swine-influenza-global-clinical-trials-review-h2-2014

Swine Influenza - Pipeline Review, H2 2014

Global Markets Direct’s, ‘Swine Influenza - Pipeline Review, H2 2014’, provides an overview of the Swine Influenza’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Swine Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Report Link: https://wiseguyreports.com/reports/swine-influenza-pipeline-review-h2-2014

It also reviews key players involved in the therapeutic development for Swine Influenza and special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope -
The report provides a snapshot of the global therapeutic landscape of Swine Influenza. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Swine Influenza and enlists all their major and minor projects 

The report summarizes all the dormant and discontinued pipeline projects. A review of the Swine Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects. Coverage of the Swine Influenza pipeline on the basis of target, MoA, route of administration and molecule type. Latest news and deals relating related to pipeline products

Reasons to buy-

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Swine Influenza. Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Swine Influenza pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Report Link: https://wiseguyreports.com/reports/swine-influenza-pipeline-review-h2-2014

Celiac Disease - Opportunity Analysis and Forecast to 2023

There are no pharmacological treatments that are indicated for celiac disease and the current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases, targeting approximately 5% of the celiac disease patient population and there are no preventative medications. The anticipated launch of Alba/Teva’s larazotide acetate in 2018 in the US and 2019 in 5EU, followed by the launch of Alvine/AbbVie’s latiglutenase in 2019 and 2020 in the US and 5EU respectively are set to change the management of the disease and drive growth in the celiac disease market. Both drugs are expected to target patients who undergo gluten exposure while on a GFD equating to approximately 95% of the celiac disease patient population. GlobalData estimates that the uptake of both drugs will be equally high, but latiglutenase will rapidly gain market value and emerge the commercially stronger drug with the backing of Immune-Gastro veteran AbbVie.

Report Link: https://wiseguyreports.com/reports/opportunity-analyzer-celiac-disease-opportunity-analysis-and-forecast-to-2023

Highlights

Key Questions Answered

- (Q.) How will the celiac disease market landscape change within the 2013-2018 and the 2013-2023 forecast periods in the 6MM?
- (Q.) What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the celiac disease market?
- (Q.) How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options?
- (Q.) What are the significant unmet needs in the celiac disease market?
- (Q.) What are the remaining opportunities in the celiac disease market?

Key Findings
- High uptake is expected of pipeline drugs for celiac disease that are anticipated to launch during the 2013-2023 forecast period.
- Celiac disease remains a field of highly unattained unmet need.
- There is no consensus over clinical trial design and endpoints for the development of celiac disease products.
- The clinical stage pipeline is mainly focussed on GFD adjunctive therapies, while the pre-clinical stage pipeline has shifted its focus to disease modifying treatments.
- Significant opportunity exists for products targeting in the non-refractory patient segment of the celiac disease market.
- M&A’s and alliance opportunities will be key factors in driving celiac disease drug development.

Scope
- Overview of celiac disease, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
- Annualized celiac disease therapeutics market revenue, annual cost of therapies and forecasts for five years to 2018 and ten years to 2023.
- Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the celiac disease therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including zonulin inhibitors, gluten peptide enzymes, gluten specific synthetic polymers and therapeutic vaccines.
- Analysis of the current and future market competition in the US and five major EU celiac disease therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.

Reasons to buy:
The report will enable you to -
- Identify the unmet needs and remaining opportunities in the celiac disease therapeutics market.
- Develop business strategies by understanding the trends shaping and driving the US and five major EU celiac disease therapeutics market.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Assess the clinical and commercial viability of promising pipeline products.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various emerging therapies.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- Drive revenues by understanding the key trends, innovative products and technologies, market and segments likely to impact the US and five major EU celiac disease therapeutics market in future.

Related Reports: https://wiseguyreports.com/related-reports

Global Breast Implants Industry 2014 Market Research Report

A breast implant is a prosthesis used to change the size, form, and texture of a woman’s breast; in plastic surgery, breast implants are applied for post–mastectomy breast reconstruction; for correcting congenital defects and deformities of the chest wall; for aesthetic breast augmentation; and for creating breasts in the male-to-female transsexual patient.
2014 Global Breast Implants Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Breast Implants industry, focusing on the main regions (North America, Europe and Asia) and the main countries (United States, Germany, Japan and China).

Link to view TOC: https://wiseguyreports.com/reports/global-breast-implants-industry-2014-market-research-report

The report firstly introduced the Breast Implants basics: definitions, classifications, applications and industry chain overview; industry policies and plans; product specifications; manufacturing processes; cost structures and so on.
Then it analyzed the world's main region market conditions, including the product price, profit, capacity, production, capacity utilization, supply, demand and industry growth rate etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Report Link: Global Breast Implants Industry 2014 Market Research Report

The report includes six parts, dealing with:
1.) basic information;
2.) the Asia Breast Implants industry;
3.) the North American Breast Implants industry;
4.) the European Breast Implants industry;
5.) market entry and investment feasibility; and
6.) the report conclusion.

Relevant Reports Link: https://www.wiseguyreports.com/categories

Contact Us:
SIDDHI MATHUR International Account Manager
www.wiseguyreports.com
siddhi.mathur@wiseguyreports.com
Ph: +44-208-133-9349 (UK) / +91 989-049-7660 (IND)

Noninvasive Cancer Diagnostics and Technologies Market Research Report Forecast 2012 - 2020

Non-invasive diagnostic is a process of identifying the disease conditions with minimal incision in body during diagnosis. The global market for diagnostic/in-vitro diagnostics valued at $49.2 billion in 2012, which shows potential for market growth, especially in chronic diseases. Non-invasive cancer diagnostics is gaining importance over conventional diagnosis due to increase in incidences of chronic cancer such as breast cancer, and lung cancer. According to American Cancer Society, there were more than 1,660,290 new cases diagnosed in 2013. Commercialization of non-invasive cancer diagnosis is possible due to completion of Human Genome Project (HGP) that gives enormous diagnostic information based on genomic and proteomic. Increase in stringent regulatory guidelines and cost associated with diagnostics is hindering the growth of non-invasive cancer diagnostic market. The Ovarian Cancer National Alliance regulations for monitoring non-invasive diagnostics are issued by FDA, Medicare and Medicaid Services (CMS) and Social Security Administration (SSA).

Research Report Link: Report- Noninvasive Cancer Diagnostics and Technologies Market - Global Share, Industry Overview, Analysis, Growth, Trends Opportunities and Forecast 2012 - 2020

The global non-invasive market has a huge potential in developing countries; however, cost of diagnosis is creating hurdles to tap this market. Hence, to overcome this problem, the diagnostic market has to be analyzed by the developing countries such as China, Japan, and India. This report provides key market drivers that are driving the market with impact analysis. The report gives intelligence about key regulatory guidelines issued by respective governments.

Key companies included in report are Precision Therapeutics, A&G Pharmaceutical, Affymetrix Inc., AVIVA Biosciences Corporation, BIOVIEW Inc., Laboratory Corporation of America Holdings (LabCorp), , Quest Diagnostics Incorporated Cancer Genetics Inc., Digene Corporation, Gen-Probe Incorporated.

Click On The Below Link To View The Research Report:
https://www.wiseguyreports.com/reports/noninvasive-cancer-diagnostics-and-technologies-market-global-share-industry-overview-analysis-growth-trends-opportunities-and-forecast-2012-2020



Contact us:

NORAH TRENT (Partner Relations & Marketing Manager)
www.wiseguyreports.com
norah.trent@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Recombinant Human Insulin Industry Research Report - 2015

2015 Deep Research Report on Global Recombinant Human Insulin Industry is a professional and depth research report on Global Recombinant Human Insulin industry.

For overview analysis, the report introduces Recombinant Human Insulin basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.

For international and China market analysis, the report analyzes Recombinant Human Insulin markets in China and other countries or regions (such as US, Russia, etc.) by presenting research on global products of different types and applications, developments and trends of market, technology, and competitive landscape, and leading suppliers and countries’ 2009-2014 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as products, customers, application, capacity, market position, and company contact information, etc. 2015-2020 forecast on capacity, production, cost, price, profit, production value, and gross margin for these markets are also included.

For technical data and manufacturing plants analysis, the report analyzes Recombinant Human Insulin leading suppliers on capacity, commercial production date, manufacturing plants distribution, R&D Status, technology sources, and raw materials sources.

This report also presents product specification, manufacturing process, and product cost structure etc. Production is separated by regions, technology and applications. Analysis also covers upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals.

In the end, the report includes Recombinant Human Insulin new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis. In conclusion, it is a deep research report on Global Recombinant Human Insulin industry.

2015 Deep Research Report on Global Recombinant Human Insulin Industry is a professional and depth research report on Global Recombinant Human Insulin industry.

For overview analysis, the report introduces Recombinant Human Insulin basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc.

For international and China market analysis, the report analyzes Recombinant Human Insulin markets in China and other countries or regions (such as US, Russia, etc.) by presenting research on global products of different types and applications, developments and trends of market, technology, and competitive landscape, and leading suppliers and countries’ 2009-2014 capacity, production, cost, price, profit, production value, and gross margin. For leading suppliers, related information is listed as products, customers, application, capacity, market position, and company contact information, etc. 2015-2020 forecast on capacity, production, cost, price, profit, production value, and gross margin for these markets are also included.

For technical data and manufacturing plants analysis, the report analyzes Recombinant Human Insulin leading suppliers on capacity, commercial production date, manufacturing plants distribution, R&D Status, technology sources, and raw materials sources.

This report also presents product specification, manufacturing process, and product cost structure etc. Production is separated by regions, technology and applications. Analysis also covers upstream raw materials, equipment, downstream client survey, marketing channels, industry development trend and proposals.

In the end, the report includes Recombinant Human Insulin new project SWOT analysis, investment feasibility analysis, investment return analysis, and development trend analysis. In conclusion, it is a deep research report on Global Recombinant Human Insulin industry.


RELEVANT REPORTS:

Global RNA Based Therapeutics Market - Forecast, 2013 - 2020
Global Biosimilars/Follow-on-Biologics Market - Forecast, 2013 - 2020